Andrea Pilotto, MD, University of Brescia, Brescia, Italy, explains a recent study that analyzed the correlation between synaptic markers and neuronal, glial, and inflammatory markers in the cerebrospinal fluid (CSF) of patients with Alzheimer’s disease. The study examined the markers neurogranin, SNAP25, and CAP2 in 20 patients with Alzheimer’s disease compared to 20 age-matched controls. Dr Pilotto stated there was a strong correlation between synaptic markers and the neuronal marker neurofilament light, a lower correlation with glial markers, and no correlation with inflammatory markers. These findings indicate that inflammation could be considered a consequence of neurodegeneration instead of cause. Dr Pilotto concluded that, as synaptic dysfunction may anticipate the neurodegenerative process, using these markers may be of interest to quantify the efficacy of investigational agents early in the disease course. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
